

| Patient Information | | | PLEASE FAX INSURANCE CARD (FRONT AND BACK) | | | Prescriber Information | | |
|---|--|-------------|--|----------------|--|------------------------|-------|-------------|
| Last Name | | First Name | | DOB | | Practice/Facility Name | | |
| Address | | | | | | Address | | |
| City | | State | | ZIP | | City | State | ZIP |
| SSN | | | | | | Prescriber Name | | |
| Sex <input type="checkbox"/> Male <input type="checkbox"/> Female | | Weight (kg) | | Height (ft.in) | | Prescriber NPI | | |
| Emergency Contact | | | | Phone | | Nurse/Key Contact | | Phone/Pager |
| Insurance Plan | | | Plan ID # | | | Fax | | |

| Diagnosis/Clinical Information | | | | | |
|---|--|---------------|----------------------------|-------|-----|
| Diagnosis <input type="checkbox"/> L40.0 Psoriasis vulgaris <input type="checkbox"/> L40.8 Other psoriasis <input type="checkbox"/> L73.2 Hidradenitis Suppurativa <input type="checkbox"/> L40.9 Psoriasis, unspecified <input type="checkbox"/> L40.5 Psoriatic arthritis <input type="checkbox"/> Other: _____ Date of diagnosis or years with the disease: _____ | | | | | |
| Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date of negative TB test: _____ | | Prior Therapy | Reason for Discontinuation | Start | End |
| Has HBV been ruled out or treatment been initiated? <input type="checkbox"/> Yes <input type="checkbox"/> No | | | | | |
| NKDA <input type="checkbox"/> Latex allergy <input type="checkbox"/> Allergies: _____ | | | | | |
| Concomitant medications: _____ | | | | | |

| Prescription Information | | | | |
|---|--|---|--------|---------|
| DRUG | DOSAGE/STRENGTH | DIRECTIONS | QTY | REFILLS |
| Cimzia <small>(Vials to be prepared and administered by healthcare professionals)</small> | <input type="checkbox"/> 200mg/mL Prefilled Syringes | Starter Dose: <input type="checkbox"/> Inject 400mg SQ at weeks 0, 2 and 4 | 6 | 0 |
| | <input type="checkbox"/> 200mg/mL Vials | Maintenance Dose: <input type="checkbox"/> Inject 400mg SQ every 4 weeks <input type="checkbox"/> Inject 200mg SQ every 2 weeks | 28 day | |
| Cosentyx | <input type="checkbox"/> 150mg/mL Sensoready Pen | Starter Dose: <input type="checkbox"/> Inject 300mg SQ once weekly at weeks 0, 1, 2, 3 and 4 <input type="checkbox"/> Inject 150mg SQ once weekly at weeks 0, 1, 2, 3 and 4 | 10 | 0 |
| | <input type="checkbox"/> 150mg/mL Prefilled Syringe | Maintenance: <input type="checkbox"/> Inject 300mg SQ every 4 weeks <input type="checkbox"/> Inject 150mg SQ every 4 weeks | 5 | |
| Enbrel | <input type="checkbox"/> 50mg/mL Sureclick Autoinjector | Starter Dose: <input type="checkbox"/> Inject 50mg SQ twice a week (72-96 hrs apart) x 3 months (Psoriasis) <input type="checkbox"/> Other: | 28 day | 2 |
| | <input type="checkbox"/> 50mg/mL Prefilled Syringe <input type="checkbox"/> 25mg/0.5mL Prefilled Syringe <input type="checkbox"/> 25mg/mL vial | Maintenance Dose: <input type="checkbox"/> Inject 50mg SQ once weekly <input type="checkbox"/> Inject 25mg SQ twice weekly (72-96 hrs apart) <input type="checkbox"/> Other: | 28 day | |
| Humira | <input type="checkbox"/> 40mg/0.8mL Pens | <input type="checkbox"/> Psoriasis Starter Pack: Inject 80mg SQ Day 1, then 40mg on Day 8, then 40mg every other week thereafter | 4 | 0 |
| | <input type="checkbox"/> 40mg/0.8mL Prefilled Syringes | Hidradenitis Suppurativa: <input type="checkbox"/> Inject 160mg SQ on Day 1, 80mg SQ on Day 15, then 40mg every week thereafter -OR- <input type="checkbox"/> Inject 80mg SQ on Day 1 and Day 2, 80mg SQ on Day 15, then 40mg every week thereafter | 6 | 0 |
| | | Maintenance Dose: <input type="checkbox"/> Inject 40mg SQ every other week <input type="checkbox"/> Inject 40mg SQ on day 29 and every week thereafter (Hidradenitis Suppurativa) | 28 day | |

Date needed: ____/____/____ Medication delivery to (choose one): Prescriber Home Other: _____
Injection training to be provided by: Prescriber's Office Hy-Vee Pharmacy Solutions Other: _____

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitution: _____
PRESCRIBER MUST MANUALLY SIGN THIS FORM - (STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED)

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date) _____ **DISPENSE AS WRITTEN/Do Not Substitute (date)** _____
I authorize Hy-Vee Pharmacy Solutions and its representatives to act as my agent in order to initiate and execute the insurance prior authorization process and, in doing so, to release clinical information via phone to the appropriate third party payer.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.